David M. Richards
University of Texas MD Anderson Cancer Center
13 Papers
13 Citations
David M. Richards is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Vedolizumab. The author has an hindex of 5, co-authored 13 publications.
Chat about Author
Papers
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
Yinghong Wang,Hamzah Abu-Sbeih,Emily Mao,Noman Ali,Wei Qiao,Van Anh Trinh,Chrystia M. Zobniw,Daniel H. Johnson,Rashmi Samdani,Phillip Lum,Gladis Shuttlesworth,Boris Blechacz,Robert S. Bresalier,Ethan Miller,Selvi Thirumurthi,David M. Richards,Gottumukkala S. Raju,John R. Stroehlein,Adi Diab +18 more
TL;DR: Endoscopic and histologic features of ICPI-induced gastrointestinal toxicities and their association with patients' clinical characteristics and outcomes are described and patients with higher-grade adverse events had improved survival.
212
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
Hamzah Abu-Sbeih,Faisal Ali,Dana Alsaadi,Joseph Jennings,Wenyi Luo,Zimu Gong,David M. Richards,Aline Charabaty,Yinghong Wang +8 more
TL;DR: Vedolizumab can be appropriate for the treatment of steroid-refractory IMDC, with favorable outcomes and a good safety profile.
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
Fangwen Zou,David Faleck,Anusha Shirwaikar Thomas,Jessica Harris,Deepika Satish,Xuemei Wang,Aline Charabaty,Marc S. Ernstoff,Isabella C. Glitza Oliva,Stephen B. Hanauer,Jennifer L. McQuade,Michel Obeid,Amishi Yogesh Shah,David M. Richards,Elad Sharon,Jedd D. Wolchok,John A. Thompson,Yinghong Wang +17 more
TL;DR: In this paper, a two-center, retrospective observational cohort study of patients with immune-mediated diarrhea and colitis who received SITs following steroids from 2016 to 2020 was performed.
80
Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors.
Tenglong Tang,Hamzah Abu-Sbeih,Wenyi Luo,Phillip Lum,Wei Qiao,Robert S. Bresalier,David M. Richards,Yinghong Wang +7 more
TL;DR: There is a correlation between ICI use and onset of upper GI inflammation even when other risk factors were excluded, and gastric involvement was evident more often than duodenal involvement on endoscopic and histological level.
68
Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy.
Tenglong Tang,Hamzah Abu-Sbeih,Weijie Ma,Yang Lu,Wenyi Luo,Wai Chin Foo,David M. Richards,Daniel M. Halperin,Phillip S. Ge,Yinghong Wang +9 more
TL;DR: ACD is a rare adverse event of AAT and is usually mild, despite its rarity, complications of ACD can be serious, requiring intensive care unit and surgery.
9